Sana Biotechnology announced 14-month follow-up data from a first-in-human study showing its UP421 therapy continued to produce insulin in a single Type 1 diabetes patient with no safety concerns12
The hypoimmune (HIP)-modified islet cells evaded immune detection for over a year without requiring immunosuppressive drugs12
C-peptide levels at 14 months remained comparable to levels during the first six months, with improved insulin secretion at month 1412
The patient demonstrated tighter glycemic control between months 12 and 14, with improved insulin response to meals1
Sana plans to submit an investigational new drug (IND) application for SC451, a stem cell-derived HIP-modified therapy designed as a one-time treatment for Type 1 diabetes12
The company expects to initiate a Phase 1 clinical trial for SC451 as early as 202612
The study was conducted at Uppsala University Hospital and supported by The Leona M. and Harry B. Helmsley Charitable Trust23
Sources:
1. https://www.fiercebiotech.com/biotech/sana-sees-14-month-insulin-production-transplanted-islet-therapy-single-type-1-diabetes
2. https://www.globenewswire.com/fr/news-release/2026/03/13/3255502/0/en/Sana-Biotechnology-Announces-Continued-Positive-Clinical-Results-Through-14-Months-from-Type-1-Diabetes-Study-of-Islet-Cell-Transplantation-Without-Immunosuppression.html
3. https://www.marketscreener.com/news/sana-biotechnology-announces-continued-positive-clinical-results-from-type-1-diabetes-study-of-islet-ce7e5fd3db8ffe26